AGENUS INC Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
AGENUS INC (AGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $6.88 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2026-03-16
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2025-03-31 was $21.25, a 49.07% decline year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2024-03-31 was $41.72.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.64.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2020-03-31 was $3.44, a 17.11% decline year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2025 was $6.88, a 68.47% decline from fiscal 2024.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $21.82, a 1054.50% increase from fiscal 2023.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $1.89, a 12.09% decline from fiscal 2022.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $2.15, a 43.27% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.88 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $21.68 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $22.53 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $21.25 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $21.82 10-K · filed 2025-03-17 | |||
| 2024-09-30 | $21.39 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $41.72 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $41.72 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $1.89 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $2.11 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.88 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $2.15 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $1.81 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $1.73 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $1.64 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $3.79 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $3.23 10-Q · filed 2021-11-09 | |||
| 2020-12-31 | $3.43 10-K · filed 2021-03-16 | |||
| 2020-09-30 | $3.44 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $3.44 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $3.44 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $4.14 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $4.15 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $4.15 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $4.15 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $4.21 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $4.26 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $4.30 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $6.21 10-K · filed 2018-03-16 | |||
| 2017-09-30 | $6.61 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $8.78 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | $8.78 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | $8.15 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $8.05 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $8.31 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $8.78 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | $7.91 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $8.57 10-Q · filed 2015-11-04 | |||
| 2015-06-30 | $3.61 10-Q · filed 2015-08-03 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-01 | |||
| 2014-12-31 | $3.59 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $3.59 10-Q · filed 2014-10-31 | |||
| 2014-06-30 | $3.40 10-Q · filed 2014-08-01 | |||
| 2014-03-31 | $3.40 10-Q · filed 2014-05-09 | |||
| 2013-12-31 | $6.30 10-K · filed 2014-03-07 | |||
| 2013-09-30 | $6.30 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | $6.30 10-Q · filed 2013-08-09 | |||
| 2013-03-31 | $6.30 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |